

GLAXOSMITHKLINE PLC

Form 6-K

March 12, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 12 March 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley  
 b) Position/status Chief Executive Officer

- c) Initial notification/  
 amendment Initial notification  
 Details of the issuer, emission allowance market participant, auction

2. platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place  
 3. where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

- b) Nature of the transaction ISIN: GB0009252882  
 Acquisition of Ordinary Shares under the Company's Share Reward Plan.

- c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £13.4317 10 (partnership shares)  
 £13.4317 10 (matching shares)

Aggregated information

- d) Aggregated volume 20 Ordinary Shares  
 Price £13.4317  
 e) Date of the transaction 2018-03-09  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor  
 b) Position/status

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

President, Global Manufacturing & Supply

- c) Initial notification/  
amendment Initial notification  
Details of the issuer, emission allowance market participant, auction  
2. platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793  
Details of the transaction(s): section to be repeated for (i) each type of  
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place  
where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each  
(‘Ordinary Shares’)

ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares  
under the Company’s Share Reward  
Plan.

- c) Price(s) and volume(s)  
Price(s) Volume(s)  
£13.4317 10 (partnership shares)  
£13.4317 10 (matching shares)

Aggregated information

- d) Aggregated volume 20 Ordinary Shares

Price £13.4317

- e) Date of the transaction 2018-03-09

- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them (‘PCA’)

- a) Name Mr S Dingemans  
b) Position/status Chief Financial Officer

- c) Initial notification/  
amendment Initial notification  
Details of the issuer, emission allowance market participant, auction  
2. platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793  
Details of the transaction(s): section to be repeated for (i) each type of  
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place  
where transaction(s) has been conducted

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £13.4317 10 (partnership shares) £13.4317 10 (matching shares)
Aggregated information	
d) Aggregated volume	20 Ordinary Shares
Price	£13.4317
e) Date of the transaction	2018-03-09
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr N Hirons
  - b) Position/status SVP, Global Ethics & Compliance
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £13.4317 10 (partnership shares) £13.4317 10 (matching shares)
d) Aggregated information	

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Aggregated volume	20 Ordinary Shares
Price	£13.4317
e) Date of the transaction	2018-03-09
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr L Miels
b) Position/status	President, Global Pharmaceuticals
c) Initial notification/ amendment	Initial notification

Details of the issuer, emission allowance market participant, auction  
2. platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
--	--

	ISIN: GB0009252882
--	--------------------

b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
------------------------------	---

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£13.4317	10 (partnership shares)
	£13.4317	10 (matching shares)

Aggregated information

d) Aggregated volume	20 Ordinary Shares
Price	£13.4317
e) Date of the transaction	2018-03-09
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr D S Redfern
b) Position/status	Chief Strategy Officer

- c) Initial notification/ amendment Initial notification  
 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
2. platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
3. where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)  
 £13.4317 10 (partnership shares)  
 £13.4317 10 (matching shares)
- Aggregated information
- d) Aggregated volume 20 Ordinary Shares  
 Price £13.4317
- e) Date of the transaction 2018-03-09  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms C Thomas  
 b) Position/status SVP, Human Resources
- c) Initial notification/ amendment Initial notification  
 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
2. platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
3. where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £13.4317 10 (partnership shares)  
 £13.4317 10 (matching shares)

Aggregated information

d) Aggregated volume 20 Ordinary Shares

Price £13.4317

e) Date of the transaction 2018-03-09

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson

b) Position/status President, Global Affairs

c) Initial notification/  
 amendment Initial notification

Details of the issuer, emission allowance market participant, auction

2. platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £13.4317 9 (partnership shares)  
 £13.4317 9 (matching shares)

d) Aggregated information

Aggregated volume 18 Ordinary Shares

Price £13.4317

e) Date of the transaction 2018-03-09

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr P J T Vallance

b) Position/status President, R&D

c) Initial notification/  
amendment Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c) Price(s) and volume(s)

Price(s)	Volume(s)
£13.4317	9 (partnership shares)
£13.4317	9 (matching shares)

Aggregated information

d) Aggregated volume 18 Ordinary Shares

Price £13.4317

e) Date of the transaction 2018-03-09

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mrs V A Whyte

b) Position/status Company Secretary

c) Initial notification/  
Initial notification



amendment

Details of the issuer, emission allowance market participant, auction

2. platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place  
 3. where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £13.4317 10 (partnership shares)  
 £13.4317 10 (matching shares)

Aggregated information

d) Aggregated volume 20 Ordinary Shares

Price £13.4317

e) Date of the transaction 2018-03-09

f) Place of the transaction London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
 (Registrant)

Date: March 12, 2018

By: VICTORIA WHYTE-----

Victoria Whyte  
 Authorised Signatory for and on  
 behalf of GlaxoSmithKline plc